In a small trial, an oral drug modestly slowed retinal damage in Stargardt disease

A small randomised trial has reported that an oral drug, gildeuretinol acetate, modestly slowed the progression of retinal damage in Stargardt disease — the most common inherited macular dystrophy, and one with no approved treatment [s1]. The results, published on 3 September in JAMA Ophthalmology, are a genuine signal in a condition that has had none, but the effect size is small and the trial is early-stage.

The disease and the trial

Stargardt disease is a genetic condition, driven by variants in the ABCA4 gene, that causes progressive loss of central vision [s1]. It is the most common macular dystrophy, and there is no approved therapy [s1].

The TEASE-1 trial was a two-year, multicentre, double-masked, placebo-controlled study run at seven US outpatient clinics, with a crossover group and additional natural-history cases selected before the statistical plan was finalised [s1][s2]. Participants were aged 12 or older, clinically diagnosed with Stargardt disease, and carried at least one disease-causing or likely disease-causing ABCA4 variant [s1]. The study was conducted between August 2015 and October 2019, with data analysed in the second half of 2020 [s1]. Participants were randomised to daily oral gildeuretinol at 14 mg or 24 mg, to placebo for 24 months, or to placebo for 12 months followed by gildeuretinol for 12 months [s1].

In total, 50 participants were randomised and 54 natural-history cases were included [s1]. The mean age of randomised participants was 44.3 years (range, 18 to 60), and 58 of 104 participants or cases (55.8%) were female [s1].

What it found

The primary endpoint was the growth rate of well-defined areas of retinal atrophy, measured over 24 months on fundus autofluorescence imaging [s1]. Lesion growth was 0.182 mm per year with gildeuretinol, compared with 0.232 mm per year in the untreated group — a combination of placebo and natural-history cases [s1]. That is a mean difference of −0.050 mm per year (95% CI, −0.072 to −0.027; P < .001), or a 21.6% relative reduction [s1].

A stricter, prespecified sensitivity analysis limited to randomised participants — dropping the natural-history comparator — found a smaller effect: growth of 0.206 mm per year with gildeuretinol versus 0.242 mm per year with placebo, a difference of −0.036 mm per year (95% CI, −0.062 to −0.009; P = .008), or a 14.9% relative reduction [s1].

On safety, most adverse events were mild or moderate and evenly distributed between groups, with no treatment-related serious adverse events, no clinically significant liver-function abnormalities, and no participant-reported night blindness or dark-adaptation difficulty [s1].

How much this means

The cautions are substantial and the authors state them. This is a 50-patient randomised trial, small by any standard, and part of the comparison relied on natural-history cases rather than only on concurrently randomised controls — which is why the effect shrank in the randomised-only analysis [s1]. The measured benefit is a fraction of a millimetre of lesion growth avoided per year, and the authors conclude plainly that "further research is needed to determine the clinical relevance of this end point" [s1]. In other words, the trial shows an effect on an imaging marker; whether that translates into vision people notice and value is the unanswered question.

There is also a timing wrinkle worth flagging: the trial itself ran from 2015 to 2019, and the full results are only now being published [s1][s2]. The finding is newly on the record even though the data are older.

Why it still matters

For a disease with no approved treatment, a positive, adequately controlled signal on a validated imaging endpoint is not nothing — it is the kind of result that justifies larger trials rather than one that settles a question. The mechanism is plausible: gildeuretinol is designed to slow the chemistry in the retina thought to drive ABCA4-related damage, so slowing atrophy is the effect one would predict if the drug works as intended. But a modest effect on lesion growth in 50 patients is a starting point, not an arrival. This article does not constitute medical advice, and gildeuretinol is not an approved therapy. What TEASE-1 delivers is a first controlled foothold in a condition that has lacked one.

Sources

• [s1] "Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease (TEASE-1)." JAMA Ophthalmology, 3 September 2026.
• [s2] ClinicalTrials.gov, "A Study to Evaluate Gildeuretinol (ALK-001) in Stargardt Disease (TEASE-1)," NCT02402660.